

KASTEN, INC.

FIRST QUARTER DISCLOSURE STATEMENT (AMENDED)

MARCH 31, 2017

Trading Symbol

KAST

1) Name of the issuer and its predecessors (if any)

Kasten, Inc.

- Formerly known as Geo Vision International Group until October 2013 and as Demco until January 1995.

2) Address of the issuer's principal executive offices

Mailing Address:

Kasten, Inc.

522 N. Main Avenue

#202

Sioux Falls, SD 57104

IR Contact

None

3) Security Information

Trading Symbol:

KAST

Exact title and class of securities outstanding:

Common

CUSIP: 48583U107

Par or Stated Value: \$0.0001

Common shares authorized: ----- 950,000,000

Total shares outstanding 03/31/17 ----- 62,501,211

Total shares outstanding 05/18/17 ----- 62,501,211

Transfer Agent

Madison Stock Transfer Inc.

PO Box 145

Brooklyn, NY 11229-0145

718-627-4453

Is the Transfer Agent registered under the Exchange Act? Yes

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months. List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

As of March 31, 2017, there were no trading suspensions, stock splits, dividends, recapitalizations, etc.

On March 3, 2017, a Kasten Merger Sub merged with and into the private company Thru Pharma, LLC, d/b/a DAKOTA Life Sciences (“DAKOTA”), with the Merger Sub as the surviving corporation. The LLC Member Interests of DAKOTA were converted into the Merger Consideration comprising 42,000,000 shares of Kasten common stock. In relation to this merger transaction, the Board of Directors authorized the Corporation to cancel the following shares totaling One Hundred Seven Million (107,000,000) of common stock for the reasons set forth below:

Prancer Inc – 50,000,000 Shares of Common Stock, 39.215% beneficially owned by Robert Rockwell; and

Tag Media Holdings, Inc. – 57,000,000 Shares of Common Stock, 44.705% beneficially owned by Michael Jacobs

Prancer Inc. and Tag Media Holdings, Inc. have agreed to the cancellation of their Shares of Common Stock in order to help effectuate the closing of the Merger between the Corporation and Thru Pharma, LLC (“DAKOTA”) pursuant to the terms of the Agreement of Merger dated March 1, 2017.

Separately, Prancer, Inc. and Tag Media Holdings, Inc. have received Warrants to purchase 2,000,000 and 12,000,000 shares of Common Stock, respectively, dated March 1, 2017.

4) Issuance History Control shares (10% or more)

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);
The shares issued by the Company were issued in accordance with the Securities & Exchange Act section 4(2).

Per the Written Consent of the Board of Directors dated April 25, 2014, the Company was authorized to issue from treasury a total of 50,000,000 new restricted shares of common stock to Prancer Inc. per the terms and conditions of the Product Marketing Agreement.

Per the Written Consent of the Board of Directors dated September 1, 2014, the Company was authorized to issue from treasury a total of 57,000,000 new restricted shares of

common stock to TAG Media per the terms and conditions of the Acquisition Agreement of 3IPPPA, an online freelancing marketplace.

B. Any jurisdictions where the offering was registered or qualified;
None

C. The number of shares offered;

D. The number of shares sold;

E. The price at which the shares were offered,
N/A

F. The trading status of the shares;
restricted

G. The certificates evidencing the shares contain a legend stating that the shares have not been registered under the Securities Act and set forth the restrictions on transferability and sale of the shares under the Securities Act. Officers, directors and control shares are restricted from sale and bear a legend setting forth the restrictions on transferability.

5) Financial Statements

The Company's unaudited financial statements are posted to the OTC Disclosure & News Service as a separate report. They were prepared in accordance with GAAP requirements by the Company's CEO, James Cahill. Mr. Cahill has served as an investment banker for many years and has sufficient knowledge to prepare the financials.

6) Describe the Issuer's Business, Products and Services

A. Date and State (or Jurisdiction) of Incorporation:
The issuer was incorporated in 1986 as a Nevada corporation.

B. The issuer's primary and secondary SIC Codes;
Primary SIC Code 7331, Secondary SIC Code 2834

C. The issuer's fiscal year end date;
December 31

D. Principal products or services, and their markets;

In Q3 of 2016, the Company refocused its business operations, and is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings.

The DAKOTA merger provides access to both Over-The-Counter (OTC) and prescription (Rx) pharmaceutical products and technologies. Distribution of these products will initially be into the podiatry and wound care markets, with additional markets in development.

Management Changes

In conjunction with the DAKOTA merger, on March 1, 2017, Jose Delgado resigned as CEO and Director and James Cahill was appointed as Chief Executive Officer, Chief Financial Officer and Director, and Steven Keough was appointed as President, Chief Operating Officer and Director.

Mike Handley was appointed Executive Chairman of the Board on August 23, 2016 to help facilitate the company's new direction. He resigned December 2, 2016 as the Company's efforts turned to raising funds to implement the company's new strategic direction.

Letter of Intent with Gulf Coast Pharmaceuticals

On December 2, 2016, the Company announced a letter of intent (LOI) with Gulf Coast Pharmaceuticals to acquire formulas for Alzheimer's disease and Erectile Dysfunction. As a result of its due diligence review, the Company decided not to pursue this opportunity.

Exclusive Sublicense Agreement

On November 7, 2016, the Company entered into an Exclusive Sublicense Agreement with a private corporation, which holds the license to International PCT Patent Application No. PCT/CA 2016/000230, under a Master License Agreement with the Governors of the University of Alberta ("UA"). The patent application is for a formulation that potentiates the activity of bacitracin by using alkyl gallates. In January, 2017, following due diligence on this technology, the Company decided not to pursue this opportunity and terminated its Exclusive Sublicense Agreement.

Term Sheet with Large Multi-national Pharmaceutical Company

On November 8, 2016, the Company entered into a Non Binding Term Sheet with a large multi-national pharmaceutical company. The Term Sheet expired and did not move forward due to lack of due diligence information for the specified products.

3IPPA

Prior to the acquisition of 3IPPA, the Company launched Kasten Mobile. This was a mobile app development company. Due to heavy competition and the landscape of the mobile app marketplace, the Company decided it was in its best interest to focus its resources exclusively on the 3IPPA opportunity.

With its acquisition of 3IPPA on September 1, 2014, the Company became an online freelancing and outsourcing marketplace. It connected employers and freelancers globally. It was described as the only time-based freelancer website where work price was dependent on the time of the programmer. In addition, unlike other freelance companies, it was not limited to workplace projects but allowed anyone to find the right person for the right job. With experts from around the world showcasing their talents, 3IPPA provided the platform to get help instantly.

The Company is exploring opportunities for the sale of 3IPPA.com, in order to focus all of its time and resources on growing its new business direction relating to the acquisition, development, and commercialization of pharmaceuticals.

7) Describe the Issuer's Facilities

The Company is in the process of obtaining a lease to a facility that will enable product fulfillment to customers, pharmaceutical manufacturing, and headquarters operations for all employees in the general New York City Metropolitan Service Area. The Company has received an April 6, 2017, letter of financial support from Commissioner Catherine H. Smith of the Connecticut Department of Economic Development (DECD). This support is comprised of a \$100,000 Small Business Express Matching Grant and a Small Business Express Job Creation Incentive loan in the amount of up to \$299,000. This loan has a ten-year term at 4% interest, with principal and interest payments deferred for the first two years of the loan. The funds from the loan and grant will be utilized for machinery and equipment, as well as leasehold improvements at the facility according to the approved Project Plan. Certain additional milestones must be met prior to accessing these DECD funds, including securing \$1 million in private (non-state) funds through equity or debt, a final executed 10 year lease to the facility, and a copy of the initial product manufacturing contract. The Company is diligently advancing each of those milestones, and working closely with the City of Bridgeport office of economic development, headed by Mr.

Thomas Gill.

8) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

On March 1, 2017, Jose Delgado resigned as CEO and Director and James Cahill was appointed as Chief Executive Officer, Chief Financial Officer and Director, and Steven Keough was appointed as President, Chief Operating Officer and Director.

DAKOTA Life Sciences 67.199% (after the DAKOTA merger and Kasten restructure)
Steven J. Keough
522 N. Main Avenue
APT 202
Sioux Falls, SD 57104

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. (Amended) Beneficial Shareholders of Greater than Ten Percent (10%)

DAKOTA Life Sciences 67.199% (after the DAKOTA merger and restructure)
Steven J. Keough
522 N. Main Avenue
APT 202
Sioux Falls, SD 57104

9) Third Party Providers

1. Investment Banker: None

2. Promoters: None

3. Legal Counsel:

Matheau J.W. Stout, Esq.
400 East Pratt Street
8th Floor
Baltimore, MD 21202
(410) 429-7076

4. Accountants or Auditor: None - Kasten financial statements are currently prepared internally; they are not reviewed or audited. The Company is reviewing this policy for operations going forward.

5. Public Relations Consultant(s): None

6. Investor Relations Consultant: None

10) Issuer Certification

I, James Cahill certify that:

I have reviewed this annual disclosure statement of Kasten, Inc. and based on the disclosure from the prior CEO, Jose Delgado, and my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 18, 2017

/s/ James Cahill

CEO